Company news

Madrigal Pharmaceuticals, Inc. news in 2026

Madrigal Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Madrigal Announces New Real-World Data at AASLD 2026 Demonstrating Improvements in Liver Stiffness and Cardiometabolic Health Markers with Rezdiffra

November 5, 2026

Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates

November 3, 2026

Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH

October 27, 2026

Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026

October 20, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

October 15, 2026

Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants

October 6, 2026

Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference

September 2, 2026

Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors

August 12, 2026

Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates

July 30, 2026

Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026

July 16, 2026

Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio

July 13, 2026

Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026

June 3, 2026

Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH

May 27, 2026

Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk

May 20, 2026

Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates

May 5, 2026

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

May 5, 2026

Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026

April 22, 2026

Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

February 23, 2026

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results

February 19, 2026

Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs

February 11, 2026

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026

February 2, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

January 22, 2026

Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)

January 21, 2026

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

January 8, 2026

Calls in 2026

Decks in 2026